Effects of antipsychotic drugs on neurotoxicity, expression of fos-like protein and c-fos mRNA in the retrosplenial cortex after administration of dizocilpine

European Journal of Pharmacology

Volumn 398, Issue 1, 2000, Pages 1-10

  Fujimura, Masatake ^a   Hashimoto, Kenji ^a   Yamagami, Keiji ^a  

^a Yoshitomi Pharmaceutical Industries Ltd   (Japan)

Author keywords

Clozapine; Dizocilpine ((+) MK 801); Immediate early gene; Neurotoxicity; NMDA receptor antagonist; Olanzapine; Retrosplenial cortex

Indexed keywords

DIZOCILPINE; HALOPERIDOL; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PENTOBARBITAL; PROTEIN C FOS; RISPERIDONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CELL VACUOLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; FEMALE; NERVE CELL; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION; HALOPERIDOL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIMBIC SYSTEM; NERVOUS SYSTEM; PIRENZEPINE; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; RISPERIDONE; RNA, MESSENGER;

EID: 0034625709     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00235-1     Document Type: Article

References (47)

1. Allen R.M., Young S.J. Phencyclidine-induced psychosis. Am. J. Psychiatry. 135:1978;1081-1084.
2. Arvanov V.L., Wang R.Y. Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine. J. Pharmacol. Exp. Ther. 289:1999;1000-1006.
3. Ashby C.R. Jr., Wang R.Y. Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse. 24:1996;349-394.
4. Bolden C., Cusack B., Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamstar ovary cells. J. Pharmacol. Exp. Ther. 260:1992;576-580.
5. Borison R.L. Recent advances in the pharmacotherapy of schizophrenia. Harvard Rev. Psychiatry. 4:1997;255-271.
6. Brosnan-Watters G., Wozniak D.F., Nardi A., Olney J.W. Parallel recovery of MK-801-induced spatial learning impairment and neuronal injury in male mice. Pharmacol. Biochem. Behav. 62:1999;111-122.
7. Corso T.D., Sesma M.A., Tenkova T.I., Der T.C., Wozniak D.F., Farber N.B., Olney J.W. Multifocal brain damage induced by phencyclidine is augmented by pilocarpine. Brain Res. 752:1997;1-14.
8. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Rev. Psychiatry. 3:1996;241-253.
9. Curran T., Gordon M.B., Rubino K.L., Sambucetti L.C. Isolation and characterization of the c-fos (rat) cDNA and analysis of post-translational modification in vitro. Oncogene. 2:1987;79-84.
10. Dragunow M., Faull R. MK-801 induces c-fos protein in thalamic and neocortical neurons of rat brain. Neurosci. Lett. 111:1990;39-45.
11. Duncan G.E., Leipzig J.N., Mailman R.B., Lieberman J.A. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res. 812:1998;65-75.
12. Ellison G. The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res. Rev. 20:1995;250-267.
13. Farber N.B., Foster J., Olney J.W. Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity. Schizophr. Res. 21:1996;33-37.
14. Fix A.S., Long G.G., Wozniak D.F., Olney J.W. Pathomorphologic effects of N-methyl-D-aspartate antagonists in the rat posterior cingulate/retrosplenial cerebral cortex: a review. Drug Dev. Res. 32:1994;147-152.
15. Gao X.-M., Shirakawa O., Du F., Tamminga C.A. Delayed regional metabolic actions of phencyclidine. Eur. J. Pharmacol. 241:1993;7-15.
16. Gao X.-M., Hashimoto T., Tamminga C.A. Phencyclidine (PCP) and dizocilpine (MK-801) exert time-dependent effects on the expression of immediate early genes in rat brain. Synapse. 29:1998;14-28.
17. Gass P., Herdegen T., Bravo R., Kiessling M. Induction and suppression of immediate early genes in specific rat brain regions by the non-competitive N-methyl-D-aspartate receptor antagonist MK-801. Neuroscience. 53:1993;749-758.
18. Hashimoto K., Tomitaka S., Bi Y., Narita N., Minabe Y., Iyo M. Rolipram, a selective phosphodiesterase type-IV inhibitor, prevents induction of heat shock protein HSP-70 and hsp-70 mRNA in rat retrosplenial cortex by the NMDA antagonist dizocilpine. Eur. J. Neurosci. 9:1997;1891-1901.
19. Hashimoto K., Tomitaka S., Narita N., Minabe Y., Iyo M. Induction of Fos protein by 3,4-methylenedioxymethamphetamine (Ecstasy) in rat brain: regional differences in pharmacological manipulation. Addict. Biol. 2:1997;317-326.
20. Herrera D.G., Robertson H.A. Activation of c-fos in the brain. Prog. Neurobiol. 50:1996;83-107.
21. Hughes P., Dragunow M. Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacol. Rev. 47:1995;133-178.
22. Hughes P., Dragunow M., Beiharz E., Lawlor P., Gluckman P. MK-801 induces immediate-early gene proteins and BDNF mRNA in rat cerebrocortical neurons. NeuroReport. 4:1993;183-186.
23. 2 antagonistic properties. J. Pharmacol. Exp. Ther. 244:1988;685-693.
24. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
25. Jevtovic-todorovic V., Newcomer J.W., Olney J.W., Farber N.B. Pilocarpine reverses clozapine and olanzapine's prevention of NMDA antagonist neurotoxicity (NAN). Abstr. Soc. Neurosci. Meet. 25:1999;1817.
26. Krystal J.H., Karper L., Pseibyl J.P., Freeman G.K., Delaney R., Bremmer J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry. 51:1994;199-214.
27. Kurumaji A., Nehls D.G., Park C.K., MuCulloch J. Effects of NMDA antagonists, MK-801 and CPP, upon local cerebral glucose use. Brain Res. 496:1989;268-284.
28. Leysen J.E., Gommeren W., Schotte A. Serotonin receptor subtypes: possible roles and implications in antipsychotic drug action. Kane J.M., Moller H.-J., Awouters F. Serotonin in Antipsychotic Treatment - Mechanisms and Clinical Practice. 1996;51-75 Marcel Dekker, New York, NY, USA.
29. Luby E.D., Cohen B.D., Rosenbaum G., Gottilieb J.S., Kelly R. Study of a new schizophrenomimetic drug - sernyl. Arch. Neurol. Psychiatry. 81:1959;363-369.
30. MacLean P.D. Introduction: perspectives on cingulate cortex in the limbic system. Vogt B.A., Gabriel M. Neurobiology of Cigulate Cortex and Limbic Thalamus. 1993;1-15 Birkhauser, Boston, MA, USA.
31. Maddock R.J. The retrosplenial cortex and emotion: new insights from functional neuroimaging of the human brain. Trends Neurosci. 22:1999;310-316.
32. Malhotra A.K., Adler C.M., Kennison S.D., Elman J., Pickar D., Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol. Psychiatry. 42:1997;664-668.
33. McCulloch J., Iversen L.L. Autoradiographic assessment of the effects of N-methyl-D-aspartate (NMDA) receptor antagonists in vivo. Neurochem. Res. 16:1991;951-963.
34. 2 receptors. Kane J.M., Moller H.-J., Awouters F. Serotonin in Antipsychotic Treatment - Mechanisms and Clinical Practice. 1996;51-75 Marcel Dekker, New York, NY, USA.
35. Mohn A.R., Gainetdinov R.R., Caron M.G., Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell. 98:1999;427-436.
36. Näkki R., Sharp F.R., Sagar S.M., Honkaniemi J. Effects of phencyclidine on immediate early gene expression in the brain. J. Neurosci. Res. 45:1996;13-27.
37. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 52:1995;998-1007.
38. Olney J.W., Labruyere L., Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 244:1989;1360-1362.
39. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1997;Academic Press, San Diego, CA, USA.
40. Sagar S.M., Sharp F.R., Curran T. Expression of c-fos protein in brain: metabolic mapping at the cellular level. Science. 240:1988;1328-1331.
41. Sharma T., Mockler D. The cognitive efficacy of atypical antipsychotics in schizophrenia. J. Clin. Psychopharmacol. 18(Suppl. 1):1998;12S-19S.
42. Smeyne R.J., Vendrell M., Hayward M., Baker S.J., Miao G.G., Schilling K., Robertson L.M., Curran T., Morgan J.I. Continuous c-fos expression precedes programmed cell death in vivo. Nature. 363:1993;166-169.
43. Sutherland R.J., Hoesing J.M. Posterior cingulate cortex and spatial memory: a microlimnology analysis. Vogt B.A., Gabriel M. Neurobiology of Cingulate Cortex and Limbic Thalamus. 1993;461-477 Birkhauser, Boston, MA, USA.
44. Tamminga C.A., Holcomb H.H., Gao X.M., Lahti C.A. Glutamate pharmacology and the treatment of schizophrenia: current status and future directions. Int. Clin. Psychopharmacol. 10(Suppl. 3):1995;29-37.
45. Van Cauteren H., Megens A.A.H.P., Lampo A., Meuldermans W. Risperidone: a overview of animal pharmacology, toxicology, and pharmacokinetics. Kane J.M., Moller H.-J., Awouters F. Serotonin in Antipsychotic Treatment - Mechanisms and Clinical Practice. 1996;51-75 Marcel Dekker, New York, NY, USA.
46. Wang R.Y., Liang X. M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice. Neuropsychopharmacology. 19:1998;74-85.
47. Weissman A., Dam M., London E.D. Alterations in local cerebral glucose utilization induced by phencyclidine. Brain Res. 435:1987;29-40.